A 63-year-old from Northern France is the second INCOR® patient living with the system for more than three years.

The Frenchman had been diagnosed with idiopathic cardiomyopathy in the summer of 2003. Prior to the implantation he had sustained two myocardial infarcts and had developed a recidivating pulmonary edema.

In early August 2003 the then 59-year-old received an INCOR® LVAD with short inflow cannula through medial implant at the CHU Henri Mondor in Créteil. Professor Daniel Loisance con-ducted the implantation that went without complications. The patient recovered well and was extubated a day after the implantation. He was discharged from the hospital early and receives an anticoagulation therapy with low weight molecular heparin. The patient has been living at home for more than three years now.

The 63-year-old was the first patient in France and the 61st patient worldwide to receive an  INCOR® LVAD. Due to patient-specific circumstances the Frenchman cannot receive a heart transplantation and received the INCOR® with the indication Destination Therapy.

The INCOR® LVAD was first implanted during a clinical study in June 2002. In March 2003 INCOR® received CE mark approval and in the meanwhile has been implanted in 317 patients.